A drug used to treat Erdheim-Chester disease (a very rare type of histiocytosis) and advanced melanoma. It is used in patients whose disease has a mutated (changed) form of a gene called BRAF. It is also being studied in the treatment of other types of cancer. Vemurafenib
blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor and a type of targeted therapy agent. Also called BRAF (V600E) kinase inhibitor RO5185426, PLX4032, RG7204, and Zelboraf.